drugset / Trial / NCT04125472
Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1
Summary
The purpose of this study is to provide expanded access to lumasiran for adults and pediatric patients with Primary Hyperoxaluria Type 1 (PH1),
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lumasiran | Small interfering RNA (siRNA) | — | Subcutaneous |